Releasing the Immune System’s Brakes Against Skin Cancer
The FDA approved the immune checkpoint inhibitor, cemiplimab-rwlc, for certain patients with locally advanced or metastatic basal cell carcinoma—the...
Progress Against Cancer
The FDA approved the immune checkpoint inhibitor, cemiplimab-rwlc, for certain patients with locally advanced or metastatic basal cell carcinoma—the...
The FDA approved a CAR T-cell therapy – a class of cancer immunotherapy – to treat certain patients with...
The FDA granted accelerated approval to the molecularly targeted therapeutic umbralisib for certain patients with marginal zone lymphoma or...
The FDA granted accelerated approval to a new oral targeted therapeutic to treat certain adult patients with the most...
The FDA approved the combination of an immune checkpoint inhibitor and a therapeutic that prevents tumors from growing blood...
The FDA approved a molecularly targeted therapeutic for treating certain patients with some rare cancers affecting the gastrointestinal system. The U.S. Food and...
The FDA approved a molecularly targeted therapeutic to treat certain pediatric patients and young adults with anaplastic large-cell lymphoma, a rare form...
The FDA approved the first once-a-day pill to lower the levels of testosterone in certain patients with prostate cancer....
The FDA approved the molecularly targeted therapeutic selinexor to be used in combination with another targeted agent and a...
The FDA has approved a new targeted therapeutic for certain patients with HER2-positive breast cancer who were previously treated with other targeted therapies....
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 48,000 members worldwide drive progress against cancer.
Donate Now